7 completed, 2 recruiting, 2 unknown, 1 terminated. 6 Phase 2, 6 Phase 3, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Completed 2, Unknown 2, Recruiting 1, Terminated 1 |
| Phase 3 | 6 | Completed 4, Recruiting 1, Unknown 1 |
| Phase 4 | 1 | Completed 1 |
Follow Placebo BID: new trials by email Literature Review of Placebo BID trials Research Report on Placebo BID
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation of the Safety and Efficacy of GLK-321 in Subjects With Demodex Blepharitis GLK-321 low dose BID, GLK-321 mid dose BID, GLK-321 high dose BID - Demodex Blepharitis | Phase 2 | Recruiting | Glaukos Corporation | 250 | 2025-12-05 | 2026-02-27 |
| Clinical Trial to Compare the Efficacy of Celiprolol to Placebo in Patients With Vascular Ehlers-Danlos Syndrome ACER-002 (celiprolol) 200 mg BID, Placebo BID - Vascular Ehlers-Danlos Syndrome | Phase 3 | Recruiting | Acer Therapeutics Inc. | 150 | 2022-11-07 | 2025-08-24 |
| Study to Assess Efficacy and Safety of VIT-2763 (Vamifeport) in Subjects With Sickle Cell Disease VIT-2763 120 mg, VIT-2763 360 mg, VIT-2763 240 mg - Sickle Cell Disease | Phase 2 | Completed | Vifor (International) Inc. | 25 | 2021-11-18 | 2025-02-18 |
| To Evaluate the Efficacy and Safety of HSK16149 Capsule in Chinese Patients With Postherpetic Neuralgia HSK16149 20mg BID, HSK16149 40mg BID, Placebo BID - Postherpetic Neuralgia | Phase 3 | Completed | Haisco Pharmaceutical Group Co., Ltd. | 372 | 2021-11-01 | 2023-02-27 |
| Effects of APIXaban on BRAIN Protection in Patients With Sinus Rhythm and Heart Failure: APIXBRAIN-HF Trial Apixaban, Placebo - Heart Failure, Sinus Rhythm | Phase 2 | Unknown | Korea University Guro Hospital | 200 | 2021-03-02 | 2021-01-20 |
| To Evaluate the Efficacy and Safety of HSK16149 Capsule in Chinese Patients With Diabetic Peripheral Neuropathic Pain HSK16149 20mg BID, HSK16149 40mg BID, HSK16149 60mg BID - Diabetic Peripheral Neuropathic Pain | Phase 2 / Phase 3 | Unknown | Haisco Pharmaceutical Group Co., Ltd. | 687 | 2020-12-02 | 2020-12-01 |
| Efficacy and Safety of SOM3355 in Huntington's Disease Chorea SOM3355 100mg BID, SOM3355 200mg BID, Placebo BID - Huntington's Chorea | Phase 2 | Completed | SOM Innovation Biotech SA | 32 | 2018-08-08 | 2019-09-16 |
| Maintenance of Remission With Budesonide Orodispersible Tablets vs. Placebo in Eosinophilic Esophagitis Budesonide 0.5mg orodispersible tablet twice daily, Budesonide 1mg orodispersible tablet twice daily, Placebo orodispersible tablet twice daily - Eosinophilic Esophagitis | Phase 3 | Completed | Dr. Falk Pharma GmbH | 204 | 2016-01-15 | 2021-10-07 |
| Study of Trabodenoson in Adults With Ocular Hypertension or Primary Open-angle Glaucoma trabodenoson 4.5% BID, trabodenoson 6.0% QD, trabodenoson 3.0% QD - Primary Open-Angle Glaucoma (POAG), Ocular Hypertension (OHT) | Phase 3 | Completed | Inotek Pharmaceuticals Corporation | 303 | 2015-09-01 | 2016-12-06 |
| Topical Ibuprofen for Delayed Onset Mulscle Soreness IBU BID, Placebo BID, IBU TID - Pain | Phase 3 | Completed | Pfizer | 205 | 2013-06-13 | 2021-09-30 |
| Safety and Efficacy of BGP-15 in Patients With Type 2 Diabetes Mellitus BGP-15 100 mg QD, BGP-15 100 mg BID, Placebo BID - Diabetes Mellitus | Phase 2 | Terminated | N-Gene Research Laboratories, Inc. | 196 | 2010-10-01 | 2014-09-29 |
| Seizures Post Intracerebral Hemorrhage valproic acid, placebo bid - Post Cerebral Hemorrhage | Phase 4 | Completed | Wolfson Medical Center | 72 | 2003-02-01 | 2014-06-12 |
Anemia (1) · Anemia, Sickle Cell (1) · Cerebrovascular Disorders (1) · Chorea (1) · Diabetes Mellitus (1) · Ehlers-Danlos Syndrome, Type IV (1) · Eosinophilic Esophagitis (1) · Glaucoma (1) · Glaucoma, Open-Angle (1) · Heart Failure (1) · Huntington Disease (1) · Neuralgia, Postherpetic (1) · Ocular Hypertension (1) · Pain (1)
Haisco Pharmaceutical Group Co., Ltd. (2) · Acer Therapeutics Inc. (1) · Dr. Falk Pharma GmbH (1) · Glaukos Corporation (1) · Inotek Pharmaceuticals Corporation (1) · Korea University Guro Hospital (1) · N-Gene Research Laboratories, Inc. (1) · Pfizer (1) · SOM Innovation Biotech SA (1) · Vifor (International) Inc. (1) · Wolfson Medical Center (1)
United States (6) · China (2) · Germany (2) · France (1) · Greece (1) · Hungary (1) · Lebanon (1) · South Korea (1) · Spain (1) · United Kingdom (1)
Cadmus C Rich, MD,MBA,CPE (1) · Eung Ju Kim, MD, PhD. (1) · Ioanna Gouni-Berthold, MD (1) · Laszlo Koranyi, MD (1) · Peter Damsbo, MD (1) · Ralph Mueller, PhD (1) · Ricardo Hermosilla, PhD (1) · Robert Ratner, MD (1)
PMID 36494329, PMID 39158916, PMID 39320907, PMID 39659429, PMID 39694205, PMID 40377855
2009 (1), 2014 (1), 2018 (1)